[{"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-001", "question": "A 14-month-old boy with genetically confirmed PMM2-CDG (p.Arg141His and p.Phe119Leu compound heterozygous variants) is scheduled for inguinal hernia repair. Preoperative coagulation studies show antithrombin III 45% (normal 80-120%), protein C 38% (normal 70-140%), and protein S 32% (normal 65-140%). All other labs are normal. What is the most appropriate perioperative management to minimize thrombotic risk?", "options": ["Proceed with surgery without prophylaxis; risk is theoretical", "Administer prophylactic enoxaparin 0.5 mg/kg subcutaneously 12 hours preoperatively and postoperatively", "Transfuse fresh frozen plasma to correct factor deficiencies before surgery", "Delay surgery indefinitely until coagulation factors normalize with nutritional support", "Administer antithrombin III concentrate 50 IU/kg immediately preoperatively"], "answer": "B", "answer_index": 1, "explanation": "PMM2-CDG causes combined antithrombin III, protein C, and protein S deficiency, creating significant thrombotic risk. For surgical prophylaxis, LMWH is recommended to address all deficient pathways. FFP provides insufficient correction and risks volume overload. ATIII concentrate alone doesn't address protein C/S deficiency. The thrombosis risk is not theoretical, with rates of 10-15% in moderate-severe cases.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues include genetically confirmed PMM2-CDG with compound heterozygous variants, low antithrombin III (45%), protein C (38%), and protein S (32%) in a 14-month-old undergoing inguinal hernia repair, with all other labs normal; these drive the need for thromboprophylaxis due to combined deficiencies increasing perioperative thrombotic risk. No main logical issues: the vignette provides sufficient details to identify a unique best answer without contradictions, underspecification, or multiple defensible options. No main medical accuracy issues: PMM2-CDG is accurately associated with these coagulation deficiencies and elevated thrombosis risk (10-15% in moderate-severe cases); LMWH (enoxaparin) is consistent with current guidelines for surgical prophylaxis in pediatric thrombophilia, addressing all deficient pathways effectively. Alternatives are appropriately inferior—A dismisses real risk, C risks volume overload with incomplete correction, D is impractical as factors may not normalize, E corrects only ATIII. Item aligns with USMLE-level knowledge on congenital disorders and perioperative management. Minimal fix: No edit needed; item is unambiguous and accurate as written.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues include genetically confirmed PMM2-CDG with compound heterozygous variants, low antithrombin III (45%), protein C (38%), and protein S (32%) in a 14-month-old undergoing inguinal hernia repair, with all other labs normal; these drive the need for thromboprophylaxis due to combined deficiencies increasing perioperative thrombotic risk. No main logical issues: the vignette provides sufficient details to identify a unique best answer without contradictions, underspecification, or multiple defensible options. No main medical accuracy issues: PMM2-CDG is accurately associated with these coagulation deficiencies and elevated thrombosis risk (10-15% in moderate-severe cases); LMWH (enoxaparin) is consistent with current guidelines for surgical prophylaxis in pediatric thrombophilia, addressing all deficient pathways effectively. Alternatives are appropriately inferior—A dismisses real risk, C risks volume overload with incomplete correction, D is impractical as factors may not normalize, E corrects only ATIII. Item aligns with USMLE-level knowledge on congenital disorders and perioperative management. Minimal fix: No edit needed; item is unambiguous and accurate as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-002", "question": "A 3-year-old girl presents with opsoclonus-myoclonus syndrome and is found to have a right adrenal neuroblastoma with favorable histology, MYCN non-amplified. After tumor resection, neurologic symptoms persist despite high-dose steroids. Which immunotherapy targeting the specific B-cell mediated pathogenesis is most appropriate?", "options": ["Rituximab 375 mg/m² weekly for 4 weeks", "Cyclophosphamide 600 mg/m² monthly for 6 months", "Intravenous immunoglobulin 2 g/kg monthly", "Alemtuzumab 30 mg daily for 5 days", "Tocilizumab 8 mg/kg every 2 weeks"], "answer": "A", "answer_index": 0, "explanation": "Opsoclonus-myoclonus syndrome is mediated by anti-neuronal antibodies produced by B-cells. Rituximab depletes B-cells and is first-line for steroid-refractory cases. IVIG is adjunctive but not primary therapy. Cyclophosphamide is less specific and more toxic. Alemtuzumab is not standard and causes profound lymphodepletion. Tocilizumab targets IL-6, not the primary antibody-mediated pathogenesis.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include a 3-year-old with opsoclonus-myoclonus syndrome (OMS) linked to favorable-histology, MYCN non-amplified right adrenal neuroblastoma; post-resection persistence of neurologic symptoms despite high-dose steroids; and the question specifying immunotherapy targeting B-cell mediated pathogenesis. These clues point to refractory paraneoplastic OMS, where anti-neuronal antibodies from B-cells drive symptoms, making B-cell depletion the targeted approach. Main logical issue(s): None; the stem provides sufficient discriminating details (e.g., steroid refractoriness, B-cell focus) to identify Rituximab as uniquely best without contradictions or underspecification, as alternatives are less specific, more toxic, or misaligned with pathogenesis. Main medical accuracy issue(s): None; the item's logic aligns with current standards, such as those from the Children's Oncology Group, where Rituximab is first-line for steroid-refractory OMS in neuroblastoma due to its CD20-targeted B-cell depletion. IVIG is supportive, cyclophosphamide is broader and riskier, alemtuzumab causes excessive immunosuppression, and tocilizumab addresses IL-6, not antibodies. Minimal fix: None required; the item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include a 3-year-old with opsoclonus-myoclonus syndrome (OMS) linked to favorable-histology, MYCN non-amplified right adrenal neuroblastoma; post-resection persistence of neurologic symptoms despite high-dose steroids; and the question specifying immunotherapy targeting B-cell mediated pathogenesis. These clues point to refractory paraneoplastic OMS, where anti-neuronal antibodies from B-cells drive symptoms, making B-cell depletion the targeted approach. Main logical issue(s): None; the stem provides sufficient discriminating details (e.g., steroid refractoriness, B-cell focus) to identify Rituximab as uniquely best without contradictions or underspecification, as alternatives are less specific, more toxic, or misaligned with pathogenesis. Main medical accuracy issue(s): None; the item's logic aligns with current standards, such as those from the Children's Oncology Group, where Rituximab is first-line for steroid-refractory OMS in neuroblastoma due to its CD20-targeted B-cell depletion. IVIG is supportive, cyclophosphamide is broader and riskier, alemtuzumab causes excessive immunosuppression, and tocilizumab addresses IL-6, not antibodies. Minimal fix: None required; the item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-003", "question": "A 7-year-old girl with McCune-Albright syndrome (confirmed GNAS R201C mutation) presents with premature thelarche, vaginal bleeding, and a growth velocity of 12 cm/year. Bone age is 10 years. Which endocrine intervention specifically targets the underlying pathophysiology of precocious puberty in this condition?", "options": ["GnRH agonist (leuprolide) 7.5 mg IM monthly", "Aromatase inhibitor (letrozole) 2.5 mg daily", "Estrogen receptor antagonist (tamoxifen) 10 mg twice daily", "Progesterone-only contraceptive (medroxyprogesterone) 10 mg daily", "Ketoconazole 200 mg twice daily"], "answer": "B", "answer_index": 1, "explanation": "In McCune-Albright syndrome, precocious puberty results from autonomous ovarian hyperfunction, not central activation. GnRH agonists are ineffective because the process is gonadotropin-independent. Aromatase inhibitors block peripheral estrogen synthesis from autonomous follicular cysts. Tamoxifen is less effective and has more side effects. Progesterone doesn't address estrogen excess. Ketoconazole has significant toxicity.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include the confirmed GNAS R201C mutation in McCune-Albright syndrome (MAS), presenting with premature thelarche, vaginal bleeding, accelerated growth velocity (12 cm/year), and advanced bone age (10 years in a 7-year-old), indicating gonadotropin-independent precocious puberty from autonomous ovarian estrogen production. These findings point to peripheral precocious puberty, where interventions must target estrogen synthesis or action directly, not central GnRH pathways. The keyed answer B (aromatase inhibitor, letrozole) fits by blocking peripheral conversion of androgens to estrogens in autonomous follicular cysts, addressing the core pathophysiology. Alternative A (GnRH agonist) is ineffective for peripheral mechanisms; C (tamoxifen) antagonizes receptors but doesn't halt estrogen production and has more side effects; D (progesterone) fails to mitigate estrogen excess; E (ketoconazole) inhibits steroidogenesis but carries significant toxicity risks. No main logical issues, as the stem provides sufficient discriminating details for a single best choice without contradictions or underspecification. No main medical accuracy issues; this aligns with current standards for MAS management, where aromatase inhibitors are a preferred option for estrogen-driven peripheral puberty per endocrine guidelines. Minimal fix: None needed; item is unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include the confirmed GNAS R201C mutation in McCune-Albright syndrome (MAS), presenting with premature thelarche, vaginal bleeding, accelerated growth velocity (12 cm/year), and advanced bone age (10 years in a 7-year-old), indicating gonadotropin-independent precocious puberty from autonomous ovarian estrogen production. These findings point to peripheral precocious puberty, where interventions must target estrogen synthesis or action directly, not central GnRH pathways. The keyed answer B (aromatase inhibitor, letrozole) fits by blocking peripheral conversion of androgens to estrogens in autonomous follicular cysts, addressing the core pathophysiology. Alternative A (GnRH agonist) is ineffective for peripheral mechanisms; C (tamoxifen) antagonizes receptors but doesn't halt estrogen production and has more side effects; D (progesterone) fails to mitigate estrogen excess; E (ketoconazole) inhibits steroidogenesis but carries significant toxicity risks. No main logical issues, as the stem provides sufficient discriminating details for a single best choice without contradictions or underspecification. No main medical accuracy issues; this aligns with current standards for MAS management, where aromatase inhibitors are a preferred option for estrogen-driven peripheral puberty per endocrine guidelines. Minimal fix: None needed; item is unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-004", "question": "A 2-month-old infant with congenital lymphocytic choriomeningitis virus (LCMV) infection presents with chorioretinitis, hydrocephalus, and periventricular calcifications. Which neuroimaging finding best distinguishes LCMV from congenital cytomegalovirus infection?", "options": ["Periventricular calcifications", "Cortical malformations", "Cerebellar hypoplasia", "Temporal lobe cysts", "Lissencephaly"], "answer": "C", "answer_index": 2, "explanation": "While both LCMV and CMV can cause periventricular calcifications, LCMV characteristically causes severe cerebellar hypoplasia due to selective infection of the external granular layer cells. CMV more commonly causes cortical malformations, temporal lobe cysts, and lissencephaly. This distinction is critical for prognosis and genetic counseling, as LCMV has a higher risk of severe neurodevelopmental disability.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: The vignette specifies a 2-month-old with confirmed congenital LCMV infection presenting with chorioretinitis, hydrocephalus, and periventricular calcifications, asking for the neuroimaging finding that best distinguishes LCMV from congenital CMV. These shared features (chorioretinitis, hydrocephalus, calcifications) set up the need for a discriminator, with options including common (A) and differential findings (B-E). Cerebellar hypoplasia (C) is characteristic of LCMV due to its tropism for cerebellar granular cells, while cortical malformations (B), temporal lobe cysts (D), and lissencephaly (E) are more typical of CMV, making C the unique best distinguisher without requiring assumptions.\\nMain logical issue(s), if any: None; the stem provides sufficient details for discrimination, with no contradictions, multiple defensible answers, or underspecification.\\nMain medical accuracy issue(s), if any: None; aligns with established knowledge that LCMV causes prominent cerebellar hypoplasia, differentiating it from CMV's cortical predominance, consistent with current pediatric neurology standards and guidelines (e.g., AAP, CDC on congenital infections). The rationale accurately notes prognostic implications.\\nMinimal fix: No fix required; the item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: The vignette specifies a 2-month-old with confirmed congenital LCMV infection presenting with chorioretinitis, hydrocephalus, and periventricular calcifications, asking for the neuroimaging finding that best distinguishes LCMV from congenital CMV. These shared features (chorioretinitis, hydrocephalus, calcifications) set up the need for a discriminator, with options including common (A) and differential findings (B-E). Cerebellar hypoplasia (C) is characteristic of LCMV due to its tropism for cerebellar granular cells, while cortical malformations (B), temporal lobe cysts (D), and lissencephaly (E) are more typical of CMV, making C the unique best distinguisher without requiring assumptions.\nMain logical issue(s), if any: None; the stem provides sufficient details for discrimination, with no contradictions, multiple defensible answers, or underspecification.\nMain medical accuracy issue(s), if any: None; aligns with established knowledge that LCMV causes prominent cerebellar hypoplasia, differentiating it from CMV's cortical predominance, consistent with current pediatric neurology standards and guidelines (e.g., AAP, CDC on congenital infections). The rationale accurately notes prognostic implications.\nMinimal fix: No fix required; the item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-005", "question": "A 5-year-old boy with DOCK8 deficiency (biallelic null variants) has recurrent Staphylococcus aureus skin abscesses, severe eczema, and recurrent pneumonias. Which prophylactic regimen specifically targets the predominant immunologic defect?", "options": ["Trimethoprim-sulfamethoxazole for Pneumocystis prophylaxis", "Penicillin VK for streptococcal prophylaxis", "Itraconazole for fungal prophylaxis", "Azithromycin for atypical mycobacterial prophylaxis", "Valganciclovir for CMV prophylaxis"], "answer": "C", "answer_index": 2, "explanation": "DOCK8 deficiency is a combined immunodeficiency with impaired T-cell function leading to susceptibility to fungal infections, particularly Candida and dermatophytes. Itraconazole provides broad antifungal prophylaxis. TMP-SMX is for Pneumocystis but doesn't address the primary defect. Penicillin doesn't cover the main pathogens. Azithromycin is for atypical mycobacteria which are less common. Valganciclovir is for CMV which can occur but isn't the primary defect.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: M (primary; secondary U). Verdict on keyed answer: Not uniquely determinable. Key stem clues that drive (or fail to drive) a unique best answer: DOCK8 deficiency (combined immunodeficiency with T-cell dysfunction), recurrent S. aureus skin abscesses (bacterial), severe eczema, recurrent pneumonias (unspecified etiology, potentially bacterial or PCP). These suggest broad susceptibilities but do not specify fungal infections, making 'predominant immunologic defect' ambiguous for prophylaxis selection. Main logical issue(s): Multiple answers defensible (M) as both A (TMP-SMX for PCP, a fungal opportunistic infection due to T-cell defect) and C (itraconazole for broader fungal prophylaxis, e.g., Candida/dermatophytes) reasonably target the T-cell-mediated susceptibility to fungi; underspecified (U) without clarifying 'predominant defect' or providing fungal history/pneumonia details to discriminate uniquely. Main medical accuracy issue(s): Item is mostly consistent with DOCK8 features (fungal/viral/bacterial risks), but rationale inaccurately claims TMP-SMX doesn't address primary defect—PCP prophylaxis does target T-cell impairment per guidelines (e.g., routine in DOCK8); itraconazole is appropriate but typically conditional on fungal history, not predominant over PCP prophylaxis. Minimal fix: Add 'and chronic mucocutaneous candidiasis' to stem to prioritize C unambiguously as targeting characteristic fungal susceptibility.\",\n  \"medical_accuracy_score\": 3,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"M\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (primary; secondary U). Verdict on keyed answer: Not uniquely determinable. Key stem clues that drive (or fail to drive) a unique best answer: DOCK8 deficiency (combined immunodeficiency with T-cell dysfunction), recurrent S. aureus skin abscesses (bacterial), severe eczema, recurrent pneumonias (unspecified etiology, potentially bacterial or PCP). These suggest broad susceptibilities but do not specify fungal infections, making 'predominant immunologic defect' ambiguous for prophylaxis selection. Main logical issue(s): Multiple answers defensible (M) as both A (TMP-SMX for PCP, a fungal opportunistic infection due to T-cell defect) and C (itraconazole for broader fungal prophylaxis, e.g., Candida/dermatophytes) reasonably target the T-cell-mediated susceptibility to fungi; underspecified (U) without clarifying 'predominant defect' or providing fungal history/pneumonia details to discriminate uniquely. Main medical accuracy issue(s): Item is mostly consistent with DOCK8 features (fungal/viral/bacterial risks), but rationale inaccurately claims TMP-SMX doesn't address primary defect—PCP prophylaxis does target T-cell impairment per guidelines (e.g., routine in DOCK8); itraconazole is appropriate but typically conditional on fungal history, not predominant over PCP prophylaxis. Minimal fix: Add 'and chronic mucocutaneous candidiasis' to stem to prioritize C unambiguously as targeting characteristic fungal susceptibility.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-006", "question": "A 28-year-old male with a dibucaine number of 20 (normal >70) and pseudocholinesterase activity of 0.2 U/mL (normal 0.5-1.2) requires emergency intubation for airway obstruction. After succinylcholine 1.5 mg/kg, apnea persists for 90 minutes. Which anesthetic agent should be avoided in future surgeries due to shared metabolic pathway?", "options": ["Rocuronium", "Ester local anesthetics (procaine, chloroprocaine)", "Vecuronium", "Cisatracurium", "Remifentanil"], "answer": "B", "answer_index": 1, "explanation": "A dibucaine number of 20 indicates homozygous atypical pseudocholinesterase. Succinylcholine and ester local anesthetics (procaine, chloroprocaine, tetracaine) are both metabolized by pseudocholinesterase. Aminosteroid relaxants (rocuronium, vecuronium) and benzylisoquinoliniums (cisatracurium) are not metabolized by this enzyme. Remifentanil is metabolized by non-specific esterases and is safe.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Anesthesiology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include low dibucaine number (20, normal >70) and pseudocholinesterase activity (0.2 U/mL, normal 0.5-1.2), indicating homozygous atypical pseudocholinesterase deficiency, with prolonged apnea after succinylcholine confirming impaired metabolism. The question asks for an agent to avoid due to shared metabolic pathway, pointing to ester local anesthetics (B) as they are hydrolyzed by pseudocholinesterase, similar to succinylcholine. Alternatives: A (rocuronium) and C (vecuronium) are aminosteroids not reliant on pseudocholinesterase; D (cisatracurium) undergoes Hofmann elimination; E (remifentanil) uses non-specific esterases. No main logical issues; stem provides sufficient details for discrimination without contradictions or underspecification. No main medical accuracy issues; aligns with standard anesthesiology knowledge on pseudocholinesterase deficiency affecting succinylcholine and ester locals (e.g., procaine), while others are safe per guidelines like ASA. Minimal fix: None required, as item is unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include low dibucaine number (20, normal >70) and pseudocholinesterase activity (0.2 U/mL, normal 0.5-1.2), indicating homozygous atypical pseudocholinesterase deficiency, with prolonged apnea after succinylcholine confirming impaired metabolism. The question asks for an agent to avoid due to shared metabolic pathway, pointing to ester local anesthetics (B) as they are hydrolyzed by pseudocholinesterase, similar to succinylcholine. Alternatives: A (rocuronium) and C (vecuronium) are aminosteroids not reliant on pseudocholinesterase; D (cisatracurium) undergoes Hofmann elimination; E (remifentanil) uses non-specific esterases. No main logical issues; stem provides sufficient details for discrimination without contradictions or underspecification. No main medical accuracy issues; aligns with standard anesthesiology knowledge on pseudocholinesterase deficiency affecting succinylcholine and ester locals (e.g., procaine), while others are safe per guidelines like ASA. Minimal fix: None required, as item is unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-007", "question": "A 45-year-old male develops dyspnea 6 hours after interscalene brachial plexus block for shoulder surgery. Chest X-ray shows elevated right hemidiaphragm. Pulmonary function tests reveal: FVC 65% predicted, FEV1 70% predicted, FEV1/FVC 85%, TLC 70% predicted. Which PFT finding is most specific for phrenic nerve palsy versus other causes of dyspnea?", "options": ["Reduced FVC", "Preserved FEV1/FVC ratio", "Reduced TLC", "Paradoxical abdominal motion on examination", "Orthopnea"], "answer": "B", "answer_index": 1, "explanation": "Phrenic nerve palsy causes restrictive physiology with proportionate reduction in FVC and FEV1, preserving the FEV1/FVC ratio. Reduced TLC confirms restriction. While paradoxical abdominal motion is seen on examination, it is not a PFT finding. Orthopnea is nonspecific. The preserved ratio in context of reduced volumes is the key PFT pattern distinguishing restrictive from obstructive disease.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Anesthesiology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: Acute dyspnea 6 hours post-interscalene brachial plexus block (known risk for phrenic nerve involvement), elevated right hemidiaphragm on CXR confirming diaphragmatic elevation, and PFT results showing reduced FVC (65% predicted), FEV1 (70% predicted), TLC (70% predicted) with preserved FEV1/FVC (85%), collectively indicating a restrictive ventilatory defect consistent with phrenic nerve palsy. These clues discriminate by highlighting a post-procedural restrictive pattern, making B (preserved FEV1/FVC ratio) the finding that specifically distinguishes it from obstructive causes of dyspnea.\\nMain logical issue(s), if any: None; the item supports a unique best answer as B identifies the key PFT feature ruling out obstruction, while alternatives are less discriminatory (A and C are nonspecific or shared with other restrictions, D and E are not PFT findings).\\nMain medical accuracy issue(s), if any: None; aligns with established knowledge that interscalene blocks commonly cause transient phrenic nerve palsy, resulting in restrictive physiology with proportionate FEV1 and FVC reductions, preserved ratio, and reduced TLC, per anesthesia and pulmonology guidelines.\\nMinimal fix: None needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: Acute dyspnea 6 hours post-interscalene brachial plexus block (known risk for phrenic nerve involvement), elevated right hemidiaphragm on CXR confirming diaphragmatic elevation, and PFT results showing reduced FVC (65% predicted), FEV1 (70% predicted), TLC (70% predicted) with preserved FEV1/FVC (85%), collectively indicating a restrictive ventilatory defect consistent with phrenic nerve palsy. These clues discriminate by highlighting a post-procedural restrictive pattern, making B (preserved FEV1/FVC ratio) the finding that specifically distinguishes it from obstructive causes of dyspnea.\nMain logical issue(s), if any: None; the item supports a unique best answer as B identifies the key PFT feature ruling out obstruction, while alternatives are less discriminatory (A and C are nonspecific or shared with other restrictions, D and E are not PFT findings).\nMain medical accuracy issue(s), if any: None; aligns with established knowledge that interscalene blocks commonly cause transient phrenic nerve palsy, resulting in restrictive physiology with proportionate FEV1 and FVC reductions, preserved ratio, and reduced TLC, per anesthesia and pulmonology guidelines.\nMinimal fix: None needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-008", "question": "A 22-year-old female with systemic lupus erythematosus presents with nihilistic delusions that her organs have 'turned to dust' and that she is already dead. CSF shows lymphocytic pleocytosis and elevated protein. Which specific autoantibody is most strongly associated with this neuropsychiatric manifestation?", "options": ["Anti-dsDNA", "Anti-NR2A (NMDA receptor)", "Anti-Ro/SSA", "Anti-phospholipid", "Anti-Sm"], "answer": "B", "answer_index": 1, "explanation": "Anti-NR2A antibodies targeting NMDA receptors correlate strongly with diffuse neuropsychiatric SLE manifestations including psychosis, delusional states, and cognitive dysfunction. Anti-dsDNA is a general SLE marker without specific neuropsychiatric correlation. Anti-Ro is associated with neonatal lupus. Antiphospholipid antibodies cause thrombotic events. Anti-Sm is specific for SLE but not associated with particular neuropsychiatric features.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: 22-year-old female with SLE presenting with nihilistic delusions (organs 'turned to dust,' already dead) and CSF showing lymphocytic pleocytosis and elevated protein, driving identification of the autoantibody most associated with this neuropsychiatric manifestation. These clues imply diffuse neuropsychiatric SLE (NPSLE) with psychotic features and CNS inflammation, uniquely supporting anti-NR2A (NMDA receptor) antibodies as the best answer due to their strong correlation with psychosis, delusions, and cognitive dysfunction in SLE. Main logical issues: none; the stem provides sufficient discriminating findings (specific delusion type and CSF abnormalities) to allow a single best answer without contradictions or underspecification. Alternatives are worse: A (anti-dsDNA) is a general SLE marker without neuropsychiatric specificity; C (anti-Ro/SSA) links to neonatal lupus/Sjogren's; D (anti-phospholipid) causes thrombotic events, not psychosis; E (anti-Sm) is SLE-specific but lacks neuropsychiatric association. Main medical accuracy issues: none; aligns with current consensus on NPSLE pathophysiology, where anti-NR2A targets NMDA receptors causing psychiatric symptoms, consistent with major guidelines and board-level knowledge. Minimal fix: none needed; item is unambiguous and accurate as written.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: 22-year-old female with SLE presenting with nihilistic delusions (organs 'turned to dust,' already dead) and CSF showing lymphocytic pleocytosis and elevated protein, driving identification of the autoantibody most associated with this neuropsychiatric manifestation. These clues imply diffuse neuropsychiatric SLE (NPSLE) with psychotic features and CNS inflammation, uniquely supporting anti-NR2A (NMDA receptor) antibodies as the best answer due to their strong correlation with psychosis, delusions, and cognitive dysfunction in SLE. Main logical issues: none; the stem provides sufficient discriminating findings (specific delusion type and CSF abnormalities) to allow a single best answer without contradictions or underspecification. Alternatives are worse: A (anti-dsDNA) is a general SLE marker without neuropsychiatric specificity; C (anti-Ro/SSA) links to neonatal lupus/Sjogren's; D (anti-phospholipid) causes thrombotic events, not psychosis; E (anti-Sm) is SLE-specific but lacks neuropsychiatric association. Main medical accuracy issues: none; aligns with current consensus on NPSLE pathophysiology, where anti-NR2A targets NMDA receptors causing psychiatric symptoms, consistent with major guidelines and board-level knowledge. Minimal fix: none needed; item is unambiguous and accurate as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-009", "question": "A 35-year-old male with treatment-resistant schizophrenia is started on clozapine. He is HLA-DQB1*05:02 positive and HLA-B*38:02 negative. Which monitoring protocol is specifically indicated based on his genetic profile?", "options": ["Weekly CBC for 52 weeks, then monthly", "Weekly CBC for 26 weeks, then every 2 weeks to 52 weeks, then monthly", "Baseline CBC, then monthly only", "Weekly CBC for 6 months, then discontinue if stable", "No CBC monitoring required"], "answer": "B", "answer_index": 1, "explanation": "HLA-DQB1*05:02 is associated with increased clozapine-induced agranulocytosis risk, requiring extended intensive monitoring for 26 weeks before tapering frequency. HLA-B*38:02 is protective. Standard protocol is weekly for 6 months, but high-risk genotypes require longer intensive monitoring as per CPIC guidelines. Discontinuing monitoring or monthly-only monitoring is unsafe in this genetic context.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: U (primary; secondary M). Verdict on keyed answer: Not uniquely determinable. Key stem clues: 35-year-old male with treatment-resistant schizophrenia starting clozapine, HLA-DQB1*05:02 positive (risk-associated), HLA-B*38:02 negative (lacks potential protective factor). These clues fail to drive a unique best answer because standard clozapine monitoring (option B) is not altered by HLA profile in accepted guidelines, yet the question frames it as 'specifically indicated based on his genetic profile,' leaving ambiguity on whether to apply standard or modified protocol. Main logical issue(s): Underspecified - missing critical detail on how the HLA types specifically modify monitoring; requires unstated assumption (e.g., extended intensive monitoring for high-risk genotypes) to select B, leading to multiple defensible answers (B as standard vs. A as hypothetically more intensive for risk). Main medical accuracy issue(s): Implied teaching point is inaccurate; no mainstream guidelines (e.g., CPIC, FDA REMS) recommend changing clozapine agranulocytosis monitoring based on HLA-DQB1*05:02 or HLA-B*38:02 - associations exist in research but do not alter standard care (weekly 6 months, biweekly next 6, monthly thereafter). Rationale misstates 'standard' as only weekly for 6 months and invents genotype-based extension. Minimal fix: Revise stem to remove 'based on his genetic profile' and omit HLA details, making question about standard monitoring for clozapine initiation, with key B correct.\",\n  \"medical_accuracy_score\": 2,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"U\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (primary; secondary M). Verdict on keyed answer: Not uniquely determinable. Key stem clues: 35-year-old male with treatment-resistant schizophrenia starting clozapine, HLA-DQB1*05:02 positive (risk-associated), HLA-B*38:02 negative (lacks potential protective factor). These clues fail to drive a unique best answer because standard clozapine monitoring (option B) is not altered by HLA profile in accepted guidelines, yet the question frames it as 'specifically indicated based on his genetic profile,' leaving ambiguity on whether to apply standard or modified protocol. Main logical issue(s): Underspecified - missing critical detail on how the HLA types specifically modify monitoring; requires unstated assumption (e.g., extended intensive monitoring for high-risk genotypes) to select B, leading to multiple defensible answers (B as standard vs. A as hypothetically more intensive for risk). Main medical accuracy issue(s): Implied teaching point is inaccurate; no mainstream guidelines (e.g., CPIC, FDA REMS) recommend changing clozapine agranulocytosis monitoring based on HLA-DQB1*05:02 or HLA-B*38:02 - associations exist in research but do not alter standard care (weekly 6 months, biweekly next 6, monthly thereafter). Rationale misstates 'standard' as only weekly for 6 months and invents genotype-based extension. Minimal fix: Revise stem to remove 'based on his genetic profile' and omit HLA details, making question about standard monitoring for clozapine initiation, with key B correct.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-010", "question": "A 7-year-old boy presents with 18-month history of progressive social withdrawal, flattened affect, disorganized speech, and tactile hallucinations of 'bugs crawling under my skin.' He has no prior developmental delays. Which specific prodromal feature best predicts conversion to definitive schizophrenia in children?", "options": ["Social isolation", "Flattened affect", "Disorganized speech", "Tactile hallucinations", "Decline in academic performance"], "answer": "D", "answer_index": 3, "explanation": "While social isolation and affective flattening are common prodromal symptoms, tactile hallucinations are uncommon in childhood and strongly predict conversion to schizophrenia spectrum disorders. Auditory hallucinations are more frequent but less specific. The presence of multimodal hallucinations, particularly somatic/tactile, increases risk substantially and warrants aggressive early intervention.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: Progressive 18-month history in a 7-year-old boy with social withdrawal, flattened affect, disorganized speech, tactile hallucinations ('bugs crawling under skin'), and no developmental delays; question seeks the prodromal feature best predicting conversion to schizophrenia in children. These clues suggest a prodromal psychosis syndrome, where tactile hallucinations stand out as an uncommon, specific attenuated positive symptom implying higher conversion risk compared to more nonspecific features like social isolation or affective flattening.\\nMain logical issue(s), if any: None; the vignette provides sufficient discriminating details to identify tactile hallucinations as uniquely predictive without contradictions or underspecification, allowing a single best answer among comparable options.\\nMain medical accuracy issue(s), if any: Consistent with mainstream knowledge on psychosis risk syndromes (e.g., SIPS criteria), where perceptual abnormalities like tactile hallucinations are strong predictors of conversion, especially if multimodal or persistent in children; rationale aligns with evidence that such hallucinations are less common and more specific than auditory ones or negative symptoms, though real-world application considers full clinical context and differential diagnoses like substance use or medical conditions.\\nMinimal fix: No edit needed; item is unambiguous and accurate, but optionally add 'persistent' to tactile hallucinations in stem for enhanced realism.\",\n  \"medical_accuracy_score\": 4,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: Progressive 18-month history in a 7-year-old boy with social withdrawal, flattened affect, disorganized speech, tactile hallucinations ('bugs crawling under skin'), and no developmental delays; question seeks the prodromal feature best predicting conversion to schizophrenia in children. These clues suggest a prodromal psychosis syndrome, where tactile hallucinations stand out as an uncommon, specific attenuated positive symptom implying higher conversion risk compared to more nonspecific features like social isolation or affective flattening.\nMain logical issue(s), if any: None; the vignette provides sufficient discriminating details to identify tactile hallucinations as uniquely predictive without contradictions or underspecification, allowing a single best answer among comparable options.\nMain medical accuracy issue(s), if any: Consistent with mainstream knowledge on psychosis risk syndromes (e.g., SIPS criteria), where perceptual abnormalities like tactile hallucinations are strong predictors of conversion, especially if multimodal or persistent in children; rationale aligns with evidence that such hallucinations are less common and more specific than auditory ones or negative symptoms, though real-world application considers full clinical context and differential diagnoses like substance use or medical conditions.\nMinimal fix: No edit needed; item is unambiguous and accurate, but optionally add 'persistent' to tactile hallucinations in stem for enhanced realism.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-011", "question": "A 14-year-old female presents with fever, weight loss, claudication in left arm, and blood pressure discrepancy of 30 mmHg between arms. MRA shows stenosis of left subclavian artery and abdominal aorta. According to childhood Takayasu arteritis criteria, which additional finding is required for definitive diagnosis?", "options": ["Elevated ESR >40 mm/hr", "Positive ANA titer >1:320", "Stenosis of >3 vascular territories", "Presence of pulmonary artery involvement", "Age at diagnosis <16 years"], "answer": "C", "answer_index": 2, "explanation": "Childhood Takayasu arteritis per EULAR/PRINTO criteria requires angiographic abnormalities plus either typical symptoms or elevated inflammatory markers, AND involvement of >3 vascular territories. Adult criteria are less stringent. Pulmonary artery involvement is supportive but not required. Age is part of classification but not a diagnostic criterion. ANA positivity is not required.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: N (primary; secondary U). Verdict on keyed answer: No defensible answer. Key stem clues: 14-year-old with fever, weight loss, left arm claudication, 30 mmHg arm BP discrepancy, MRA stenosis in left subclavian artery and abdominal aorta (two vascular territories), driving potential Takayasu arteritis diagnosis but already meeting criteria without additional findings. Main logical issue(s): Vignette satisfies EULAR/PRINTO/PReS childhood Takayasu arteritis criteria (mandatory angiographic abnormality plus claudication and BP discrepancy >10 mmHg), so no additional finding is required for definitive diagnosis; none of the options can be defended as 'required,' rendering the item unsolvable (N). Secondarily, question assumes incompleteness without specifying missing elements like acute phase reactants, making it underspecified (U). Main medical accuracy issue(s): Keyed answer C and rationale inaccurately claim >3 vascular territories required per EULAR/PRINTO; actual criteria need only angiographic changes plus ≥1 of 5 features (no territory count). Options include irrelevant (B, ANA) or non-required findings (D, pulmonary; E, age already met). Intended teaching point misrepresents standard criteria, potentially misleading learners. Minimal fix: Revise question to 'Which finding is NOT required?' and key to C, aligning with accurate criteria.\",\n  \"medical_accuracy_score\": 2,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"N\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: N (primary; secondary U). Verdict on keyed answer: No defensible answer. Key stem clues: 14-year-old with fever, weight loss, left arm claudication, 30 mmHg arm BP discrepancy, MRA stenosis in left subclavian artery and abdominal aorta (two vascular territories), driving potential Takayasu arteritis diagnosis but already meeting criteria without additional findings. Main logical issue(s): Vignette satisfies EULAR/PRINTO/PReS childhood Takayasu arteritis criteria (mandatory angiographic abnormality plus claudication and BP discrepancy >10 mmHg), so no additional finding is required for definitive diagnosis; none of the options can be defended as 'required,' rendering the item unsolvable (N). Secondarily, question assumes incompleteness without specifying missing elements like acute phase reactants, making it underspecified (U). Main medical accuracy issue(s): Keyed answer C and rationale inaccurately claim >3 vascular territories required per EULAR/PRINTO; actual criteria need only angiographic changes plus ≥1 of 5 features (no territory count). Options include irrelevant (B, ANA) or non-required findings (D, pulmonary; E, age already met). Intended teaching point misrepresents standard criteria, potentially misleading learners. Minimal fix: Revise question to 'Which finding is NOT required?' and key to C, aligning with accurate criteria.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-012", "question": "A 3-week-old neonate presents with intractable seizures unresponsive to phenobarbital and levetiracetam. EEG shows burst-suppression pattern. CSF neurotransmitter analysis shows elevated 3-methoxy-4-hydroxyphenylglycol (MHPG) and reduced homovanillic acid (HVA). Which specific enzyme deficiency is suggested by this pattern?", "options": ["Pyridoxine 5'-phosphate oxidase", "GABA transaminase", "Aromatic L-amino acid decarboxylase", "Pyridoxal kinase", "Succinic semialdehyde dehydrogenase"], "answer": "A", "answer_index": 0, "explanation": "Pyridoxine 5'-phosphate oxidase (PNPO) deficiency impairs conversion of pyridoxine 5'-phosphate to pyridoxal 5'-phosphate, the active cofactor for GABA synthesis. CSF shows elevated MHPG/HVA ratio >2.5, which is pathognomonic. AADC deficiency shows reduced HVA and 5-HIAA. Pyridoxal kinase deficiency has different metabolite ratios. SSADH deficiency shows elevated GABA.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 3-week-old neonate with intractable seizures unresponsive to phenobarbital and levetiracetam, burst-suppression EEG, CSF with elevated MHPG and reduced HVA, suggesting a specific enzyme deficiency in neurotransmitter metabolism. These clues point to PNPO deficiency, as it impairs pyridoxal 5'-phosphate synthesis, crucial for GABA and monoamine pathways, leading to the described CSF pattern (elevated MHPG/HVA ratio). Main logical issue(s): None; the stem provides sufficient discriminating details to identify A as uniquely best, with alternatives mismatched (e.g., AADC typically shows low MHPG alongside low HVA/5-HIAA; SSADH shows elevated GABA). Main medical accuracy issue(s): None; aligns with current standards on inborn errors of metabolism, where PNPO deficiency presents with refractory neonatal seizures and this pathognomonic CSF profile, distinguishing it from similar disorders like AADC or pyridoxine dependencies. The rationale accurately contrasts options based on metabolite patterns. Minimal fix: None needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 3-week-old neonate with intractable seizures unresponsive to phenobarbital and levetiracetam, burst-suppression EEG, CSF with elevated MHPG and reduced HVA, suggesting a specific enzyme deficiency in neurotransmitter metabolism. These clues point to PNPO deficiency, as it impairs pyridoxal 5'-phosphate synthesis, crucial for GABA and monoamine pathways, leading to the described CSF pattern (elevated MHPG/HVA ratio). Main logical issue(s): None; the stem provides sufficient discriminating details to identify A as uniquely best, with alternatives mismatched (e.g., AADC typically shows low MHPG alongside low HVA/5-HIAA; SSADH shows elevated GABA). Main medical accuracy issue(s): None; aligns with current standards on inborn errors of metabolism, where PNPO deficiency presents with refractory neonatal seizures and this pathognomonic CSF profile, distinguishing it from similar disorders like AADC or pyridoxine dependencies. The rationale accurately contrasts options based on metabolite patterns. Minimal fix: None needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-013", "question": "A 2-month-old infant presents with heart failure, mitral regurgitation, and echocardiographic finding of retrograde flow in a dilated left coronary artery during diastole. Which additional echocardiographic finding is pathognomonic for anomalous left coronary artery from pulmonary artery (ALCAPA)?", "options": ["Left ventricular dilation", "Papillary muscle dysfunction", "Septal wall motion abnormalities", "Coronary artery collaterals with 'seagull' sign", "Right coronary artery dilation"], "answer": "D", "answer_index": 3, "explanation": "In ALCAPA, extensive intercoronary collaterals develop with characteristic bidirectional flow seen on color Doppler as a 'seagull' sign. While LV dilation, papillary muscle dysfunction, and RCA dilation are seen, they are not pathognomonic. The seagull sign represents collaterals from RCA to LCA with flow reversal into PA, which is diagnostic of ALCAPA.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include a 2-month-old infant with heart failure, mitral regurgitation, and retrograde diastolic flow in a dilated left coronary artery, pointing to ALCAPA; the question seeks the pathognomonic additional echocardiographic finding. The clinical problem asks for the specific echo sign diagnostic of ALCAPA. Discriminating findings: retrograde flow in dilated LCA during diastole implies anomalous origin from pulmonary artery, with collaterals developing. Most likely diagnosis: ALCAPA. Keyed answer D (Coronary artery collaterals with 'seagull' sign) fits as it represents the characteristic bidirectional flow on color Doppler from intercoronary collaterals, reversing into the pulmonary artery, which is pathognomonic. Alternatives: A (LV dilation) is common in cardiomyopathy but nonspecific; B (papillary muscle dysfunction) relates to ischemia but not unique; C (septal wall motion abnormalities) occurs in various conditions; E (RCA dilation) is supportive but not diagnostic alone. No main logical issues; stem allows discrimination of one best option without contradictions or underspecification. No main medical accuracy issues; aligns with standard pediatric cardiology knowledge on ALCAPA, where 'seagull' sign is a recognized diagnostic feature per guidelines. Minimal fix: None needed; item is unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include a 2-month-old infant with heart failure, mitral regurgitation, and retrograde diastolic flow in a dilated left coronary artery, pointing to ALCAPA; the question seeks the pathognomonic additional echocardiographic finding. The clinical problem asks for the specific echo sign diagnostic of ALCAPA. Discriminating findings: retrograde flow in dilated LCA during diastole implies anomalous origin from pulmonary artery, with collaterals developing. Most likely diagnosis: ALCAPA. Keyed answer D (Coronary artery collaterals with 'seagull' sign) fits as it represents the characteristic bidirectional flow on color Doppler from intercoronary collaterals, reversing into the pulmonary artery, which is pathognomonic. Alternatives: A (LV dilation) is common in cardiomyopathy but nonspecific; B (papillary muscle dysfunction) relates to ischemia but not unique; C (septal wall motion abnormalities) occurs in various conditions; E (RCA dilation) is supportive but not diagnostic alone. No main logical issues; stem allows discrimination of one best option without contradictions or underspecification. No main medical accuracy issues; aligns with standard pediatric cardiology knowledge on ALCAPA, where 'seagull' sign is a recognized diagnostic feature per guidelines. Minimal fix: None needed; item is unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-014", "question": "A 3-week-old neonate presents with watery diarrhea, dehydration, and metabolic alkalosis. Stool chloride is 120 mEq/L (normal <20). Genetic testing confirms CLCN5 mutation. Which electrolyte pattern is most specific for congenital chloride diarrhea versus other causes of neonatal secretory diarrhea?", "options": ["Hypochloremia, hyponatremia, metabolic alkalosis", "Hypochloremia, hyponatremia, metabolic acidosis", "Hyperchloremia, hypernatremia, metabolic alkalosis", "Hyperchloremia, hyponatremia, metabolic alkalosis", "Normal chloride, hyponatremia, metabolic acidosis"], "answer": "A", "answer_index": 0, "explanation": "CLCN5 mutation impairs ileal chloride-bicarbonate exchange, causing massive chloride loss, hypochloremia, and secondary metabolic alkalosis. Hyponatremia occurs from volume contraction. This contrasts with other secretory diarrheas which typically cause metabolic acidosis. Stool chloride >90 mEq/L is diagnostic and distinguishes it from other causes.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: C (primary; secondary U). Verdict on keyed answer: Not uniquely determinable due to internal contradiction. Key stem clues: 3-week-old with watery diarrhea, dehydration, metabolic alkalosis, stool Cl 120 mEq/L (>normal <20), CLCN5 mutation confirmation. These drive toward congenital chloride diarrhea (CCD) diagnosis, featuring chloride loss, hypochloremia, hyponatremia from dehydration, and alkalosis distinguishing from acidotic secretory diarrheas. However, they fail to uniquely support a best answer because CLCN5 mutation (Dent disease) does not cause gastrointestinal chloride loss or match the vignette's diarrheal phenotype. Main logical issue: Contradiction—the confirmed CLCN5 mutation causes renal tubulopathy (proteinuria, hypercalciuria), not neonatal secretory diarrhea with high stool Cl, making the item incoherent and unsolvable without ignoring the genetic detail. This underspecifies the true etiology, potentially allowing multiple interpretations. Main medical accuracy issues: Factual error attributing CLCN5 to CCD (actually SLC26A3 mutation impairs Cl-HCO3 exchange); rationale incorrectly states CLCN5 impairs ileal exchange. Item misleads on genetics and pathophysiology, contradicting standard knowledge. Minimal fix: Edit stem to 'Genetic testing confirms SLC26A3 mutation' to align with CCD, resolving contradiction and ensuring accuracy.\",\n  \"medical_accuracy_score\": 2,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"C\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: C (primary; secondary U). Verdict on keyed answer: Not uniquely determinable due to internal contradiction. Key stem clues: 3-week-old with watery diarrhea, dehydration, metabolic alkalosis, stool Cl 120 mEq/L (>normal <20), CLCN5 mutation confirmation. These drive toward congenital chloride diarrhea (CCD) diagnosis, featuring chloride loss, hypochloremia, hyponatremia from dehydration, and alkalosis distinguishing from acidotic secretory diarrheas. However, they fail to uniquely support a best answer because CLCN5 mutation (Dent disease) does not cause gastrointestinal chloride loss or match the vignette's diarrheal phenotype. Main logical issue: Contradiction—the confirmed CLCN5 mutation causes renal tubulopathy (proteinuria, hypercalciuria), not neonatal secretory diarrhea with high stool Cl, making the item incoherent and unsolvable without ignoring the genetic detail. This underspecifies the true etiology, potentially allowing multiple interpretations. Main medical accuracy issues: Factual error attributing CLCN5 to CCD (actually SLC26A3 mutation impairs Cl-HCO3 exchange); rationale incorrectly states CLCN5 impairs ileal exchange. Item misleads on genetics and pathophysiology, contradicting standard knowledge. Minimal fix: Edit stem to 'Genetic testing confirms SLC26A3 mutation' to align with CCD, resolving contradiction and ensuring accuracy.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "C", "verdict": "FAIL", "fail_reason": "C"}, "judge_verdict": "FAIL", "judge_fail_reason": "C", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-015", "question": "A 6-year-old boy presents with low molecular weight proteinuria, hypercalciuria, and nephrocalcinosis. Genetic testing confirms OCRL1 mutation (Dent disease type 2). Which specific tubular transport defect is characteristic of Dent disease?", "options": ["Proximal tubular phosphate reabsorption defect", "Proximal tubular glucose reabsorption defect", "Loop of Henle chloride reabsorption defect", "Distal tubular proton secretion defect", "Collecting duct water reabsorption defect"], "answer": "A", "answer_index": 0, "explanation": "Dent disease is caused by OCRL1 or CLCN5 mutations affecting proximal tubular endocytosis via the megalin/cubilin pathway, causing low molecular weight proteinuria, hypercalciuria, and phosphate wasting. It does not primarily affect glucose, chloride, proton, or water transport. The proximal tubular phosphate defect distinguishes it from other tubular disorders.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: The vignette describes a 6-year-old boy with low molecular weight proteinuria, hypercalciuria, nephrocalcinosis, and confirmed OCRL1 mutation (Dent disease type 2), asking for the characteristic tubular transport defect. These clues point to proximal tubular dysfunction affecting endocytosis, leading to phosphate wasting as a key feature distinguishing it from other tubulopathies.\\nMain logical issue(s), if any: None; the stem provides sufficient discriminating details (e.g., LMW proteinuria without glycosuria or other Fanconi features) to support A as uniquely best, with alternatives clearly inferior (B: glucose defect absent; C: loop chloride as in Bartter, mismatched; D: distal proton as in RTA, no acidosis mentioned; E: collecting duct water as in NDI, no polyuria).\\nMain medical accuracy issue(s), if any: None; aligns with standard knowledge that Dent disease involves megalin/cubilin pathway defects causing phosphaturia, hypercalciuria, and LMW proteinuria, per guidelines like those from KDIGO and genetic databases. Rationale accurately notes phosphate wasting without primary effects on glucose, chloride, proton, or water transport.\\nMinimal fix: No fix needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: The vignette describes a 6-year-old boy with low molecular weight proteinuria, hypercalciuria, nephrocalcinosis, and confirmed OCRL1 mutation (Dent disease type 2), asking for the characteristic tubular transport defect. These clues point to proximal tubular dysfunction affecting endocytosis, leading to phosphate wasting as a key feature distinguishing it from other tubulopathies.\nMain logical issue(s), if any: None; the stem provides sufficient discriminating details (e.g., LMW proteinuria without glycosuria or other Fanconi features) to support A as uniquely best, with alternatives clearly inferior (B: glucose defect absent; C: loop chloride as in Bartter, mismatched; D: distal proton as in RTA, no acidosis mentioned; E: collecting duct water as in NDI, no polyuria).\nMain medical accuracy issue(s), if any: None; aligns with standard knowledge that Dent disease involves megalin/cubilin pathway defects causing phosphaturia, hypercalciuria, and LMW proteinuria, per guidelines like those from KDIGO and genetic databases. Rationale accurately notes phosphate wasting without primary effects on glucose, chloride, proton, or water transport.\nMinimal fix: No fix needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-016", "question": "A 6-year-old child with CYP2D6 ultra-rapid metabolizer genotype (gene duplication) undergoes tonsillectomy. Postoperatively, he receives codeine 1 mg/kg q6h for pain. Which specific monitoring parameter is most critical in the first 24 hours to detect opioid toxicity?", "options": ["Respiratory rate every 4 hours", "Continuous pulse oximetry for 24 hours", "Pain score assessment every 2 hours", "Sedation score every hour for 8 hours", "Capnography for 12 hours"], "answer": "B", "answer_index": 1, "explanation": "CYP2D6 ultra-rapid metabolizers convert codeine to morphine at rates 2-10x normal, causing unpredictable and life-threatening respiratory depression. The FDA specifically contraindicates codeine in these children post-tonsillectomy. Continuous pulse oximetry is most sensitive for detecting early respiratory depression. Sedation scores are less reliable. Capnography is not standard of care.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Anesthesiology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: 6-year-old with CYP2D6 ultra-rapid metabolizer genotype (gene duplication) post-tonsillectomy receiving codeine 1 mg/kg q6h, implying high risk of rapid conversion to morphine and opioid toxicity like respiratory depression. These drive need for continuous monitoring of respiratory status over 24 hours. Main logical issue(s): None; stem provides sufficient details for discrimination, with options varying in continuity, frequency, and relevance, allowing unique best (B) as it offers full 24-hour continuous oxygenation monitoring, superior to intermittent (A), non-toxicity-focused (C), limited-duration sedation (D), or shorter capnography (E). Main medical accuracy issue(s): Mostly consistent with guidelines on opioid risks in ultra-rapid metabolizers (FDA contraindication noted in rationale); however, minor inaccuracy in rationale claiming pulse oximetry as 'most sensitive' for early respiratory depression, as capnography often detects hypoventilation earlier, though not universally standard and option E limited to 12 hours. Item aligns with board-relevant teaching on pharmacogenetics and postoperative monitoring. Minimal fix: Revise rationale to acknowledge capnography's sensitivity advantage while noting pulse oximetry's practicality and standard use.\",\n  \"medical_accuracy_score\": 3,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: 6-year-old with CYP2D6 ultra-rapid metabolizer genotype (gene duplication) post-tonsillectomy receiving codeine 1 mg/kg q6h, implying high risk of rapid conversion to morphine and opioid toxicity like respiratory depression. These drive need for continuous monitoring of respiratory status over 24 hours. Main logical issue(s): None; stem provides sufficient details for discrimination, with options varying in continuity, frequency, and relevance, allowing unique best (B) as it offers full 24-hour continuous oxygenation monitoring, superior to intermittent (A), non-toxicity-focused (C), limited-duration sedation (D), or shorter capnography (E). Main medical accuracy issue(s): Mostly consistent with guidelines on opioid risks in ultra-rapid metabolizers (FDA contraindication noted in rationale); however, minor inaccuracy in rationale claiming pulse oximetry as 'most sensitive' for early respiratory depression, as capnography often detects hypoventilation earlier, though not universally standard and option E limited to 12 hours. Item aligns with board-relevant teaching on pharmacogenetics and postoperative monitoring. Minimal fix: Revise rationale to acknowledge capnography's sensitivity advantage while noting pulse oximetry's practicality and standard use.", "medical_accuracy_score": 3, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-017", "question": "A 30-year-old female with acute intermittent porphyria requires general anesthesia for laparoscopic cholecystectomy. Which anesthetic agent is specifically contraindicated due to its porphyrinogenic effect?", "options": ["Propofol", "Sevoflurane", "Etomidate", "Thiopental", "Desflurane"], "answer": "D", "answer_index": 3, "explanation": "Barbiturates like thiopental are absolutely contraindicated in acute porphyrias as they strongly induce hepatic ALA synthase, triggering life-threatening attacks. Propofol, etomidate, and volatile agents (sevoflurane, desflurane) are considered safe. The question tests knowledge of specific porphyrinogenic drugs that must be avoided in this population.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Anesthesiology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include the patient's diagnosis of acute intermittent porphyria (AIP), the need for general anesthesia during laparoscopic cholecystectomy, and the specific query for an anesthetic agent contraindicated due to its porphyrinogenic effect. These clues point to avoiding drugs that induce hepatic ALA synthase, exacerbating AIP attacks. The keyed answer D (Thiopental) fits perfectly as it is a barbiturate known to strongly induce ALA synthase, potentially triggering life-threatening porphyric crises. Alternatives are inferior: A (Propofol) is safe and commonly used in AIP; B (Sevoflurane) and E (Desflurane) are non-porphyrinogenic volatile agents; C (Etomidate) is also considered safe for induction in this population. No main logical issues, as the stem is internally consistent, provides sufficient details to discriminate options, and supports D as the unique best choice without requiring unstated assumptions. No main medical accuracy issues; the item's logic aligns with current standards, such as guidelines from the American Porphyria Foundation and anesthesia societies, which contraindicate barbiturates in AIP while endorsing propofol, etomidate, and volatiles as safe. Minimal fix: None required, as the item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include the patient's diagnosis of acute intermittent porphyria (AIP), the need for general anesthesia during laparoscopic cholecystectomy, and the specific query for an anesthetic agent contraindicated due to its porphyrinogenic effect. These clues point to avoiding drugs that induce hepatic ALA synthase, exacerbating AIP attacks. The keyed answer D (Thiopental) fits perfectly as it is a barbiturate known to strongly induce ALA synthase, potentially triggering life-threatening porphyric crises. Alternatives are inferior: A (Propofol) is safe and commonly used in AIP; B (Sevoflurane) and E (Desflurane) are non-porphyrinogenic volatile agents; C (Etomidate) is also considered safe for induction in this population. No main logical issues, as the stem is internally consistent, provides sufficient details to discriminate options, and supports D as the unique best choice without requiring unstated assumptions. No main medical accuracy issues; the item's logic aligns with current standards, such as guidelines from the American Porphyria Foundation and anesthesia societies, which contraindicate barbiturates in AIP while endorsing propofol, etomidate, and volatiles as safe. Minimal fix: None required, as the item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-018", "question": "A 28-year-old female with SLE presents with psychosis, catatonia, and seizures. CSF shows anti-NR2A antibodies. Which specific immunosuppressive regimen is most effective for antibody-mediated neuropsychiatric SLE?", "options": ["High-dose steroids alone", "Cyclophosphamide 500 mg/m² monthly", "Rituximab 375 mg/m² weekly × 4 plus high-dose steroids", "Mycophenolate mofetil 2 g daily", "Intravenous immunoglobulin 2 g/kg monthly"], "answer": "C", "answer_index": 2, "explanation": "Anti-NR2A antibody-mediated neuropsychiatric SLE requires B-cell depletion with rituximab plus high-dose steroids. Steroids alone are insufficient. Cyclophosphamide is less effective for antibody-mediated disease. Mycophenolate is maintenance therapy. IVIG is adjunctive. The combination of rituximab and steroids provides rapid clearance of pathogenic antibodies.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 28-year-old female with SLE presenting with psychosis, catatonia, and seizures; CSF positive for anti-NR2A antibodies, indicating antibody-mediated neuropsychiatric SLE (NPSLE). These findings imply a need for rapid B-cell depletion to clear pathogenic antibodies, combined with anti-inflammatory therapy. The question asks for the most effective specific immunosuppressive regimen, and option C (rituximab 375 mg/m² weekly ×4 plus high-dose steroids) aligns with this by targeting antibody production and inflammation. Main logical issue(s), if any: None; the stem provides sufficient discriminating details (specific antibodies and symptoms) to support C as uniquely best without contradictions or underspecification. Alternatives are defensibly inferior: A lacks B-cell targeting; B (cyclophosphamide) is less specific for antibody-mediated disease; D (mycophenolate) is for maintenance, not acute; E (IVIG) is adjunctive only. Main medical accuracy issue(s), if any: Consistent with current literature on anti-NMDAR antibody-associated NPSLE, where rituximab plus steroids is reported effective in case series and expert recommendations; no major inaccuracies, though evidence is not RCT-based but aligns with mainstream rheumatology guidance (e.g., EULAR). Minimal fix: None needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 4,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 28-year-old female with SLE presenting with psychosis, catatonia, and seizures; CSF positive for anti-NR2A antibodies, indicating antibody-mediated neuropsychiatric SLE (NPSLE). These findings imply a need for rapid B-cell depletion to clear pathogenic antibodies, combined with anti-inflammatory therapy. The question asks for the most effective specific immunosuppressive regimen, and option C (rituximab 375 mg/m² weekly ×4 plus high-dose steroids) aligns with this by targeting antibody production and inflammation. Main logical issue(s), if any: None; the stem provides sufficient discriminating details (specific antibodies and symptoms) to support C as uniquely best without contradictions or underspecification. Alternatives are defensibly inferior: A lacks B-cell targeting; B (cyclophosphamide) is less specific for antibody-mediated disease; D (mycophenolate) is for maintenance, not acute; E (IVIG) is adjunctive only. Main medical accuracy issue(s), if any: Consistent with current literature on anti-NMDAR antibody-associated NPSLE, where rituximab plus steroids is reported effective in case series and expert recommendations; no major inaccuracies, though evidence is not RCT-based but aligns with mainstream rheumatology guidance (e.g., EULAR). Minimal fix: None needed; item is already unambiguous and accurate.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-019", "question": "A 78-year-old female with major depressive disorder is started on sertraline 50 mg daily. She has SIADH risk factors: age >65, female, concomitant thiazide diuretic. Which electrolyte monitoring protocol is recommended?", "options": ["Baseline sodium only", "Baseline and 1-week sodium", "Baseline, 1-week, and 2-week sodium", "Baseline, 1-week, 2-week, and 4-week sodium", "Weekly sodium for 8 weeks"], "answer": "D", "answer_index": 3, "explanation": "SIADH from SSRIs typically occurs within 2-4 weeks. High-risk patients (elderly, female, diuretic use) require sodium monitoring at baseline, 1, 2, and 4 weeks. More frequent monitoring is unnecessary if stable. Baseline alone or single follow-up is insufficient. Weekly monitoring for 8 weeks is excessive and not guideline-recommended.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include the patient's age (78, >65), female sex, concomitant thiazide diuretic use, and initiation of sertraline, all established risk factors for SSRI-induced SIADH, which typically manifests within 2-4 weeks. These clues imply the need for targeted sodium monitoring in high-risk patients to detect hyponatremia early, supporting a protocol that covers the initial high-risk period without excess. The question asks for the recommended electrolyte monitoring protocol, restating the clinical problem as selecting optimal sodium surveillance for SIADH risk in an elderly female on SSRI and diuretic. Key discriminating findings: positive (advanced age, female, diuretic); negative (no mention of prior hyponatremia or other risks). Most likely next step: serial sodium checks at baseline and follow-ups aligning with onset timeline. Keyed answer D fits as it monitors at baseline, 1, 2, and 4 weeks, matching typical risk window. Alternatives: A insufficient (no follow-up); B limited (misses 2-4 weeks); C misses 4 weeks; E excessive (weekly for 8 weeks unnecessary if stable). No main logical issues; item supports unique best answer without contradictions or underspecification. No main medical accuracy issues; aligns with mainstream psychopharmacology guidance on SSRI-SIADH monitoring in high-risk groups, though exact protocols can vary by guideline (e.g., APA suggests monitoring but not always this specific cadence). Minimal fix: No fix required; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include the patient's age (78, >65), female sex, concomitant thiazide diuretic use, and initiation of sertraline, all established risk factors for SSRI-induced SIADH, which typically manifests within 2-4 weeks. These clues imply the need for targeted sodium monitoring in high-risk patients to detect hyponatremia early, supporting a protocol that covers the initial high-risk period without excess. The question asks for the recommended electrolyte monitoring protocol, restating the clinical problem as selecting optimal sodium surveillance for SIADH risk in an elderly female on SSRI and diuretic. Key discriminating findings: positive (advanced age, female, diuretic); negative (no mention of prior hyponatremia or other risks). Most likely next step: serial sodium checks at baseline and follow-ups aligning with onset timeline. Keyed answer D fits as it monitors at baseline, 1, 2, and 4 weeks, matching typical risk window. Alternatives: A insufficient (no follow-up); B limited (misses 2-4 weeks); C misses 4 weeks; E excessive (weekly for 8 weeks unnecessary if stable). No main logical issues; item supports unique best answer without contradictions or underspecification. No main medical accuracy issues; aligns with mainstream psychopharmacology guidance on SSRI-SIADH monitoring in high-risk groups, though exact protocols can vary by guideline (e.g., APA suggests monitoring but not always this specific cadence). Minimal fix: No fix required; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-020", "question": "A 35-year-old male in a personal injury lawsuit reports severe chronic pain despite normal examinations and imaging. He is observed to be inconsistent in his symptom presentation between evaluations. Which specific criterion best distinguishes malingering from factitious disorder in this scenario?", "options": ["Presence of secondary gain", "Intentional production of symptoms", "Lack of insight into psychological factors", "Symptoms are under voluntary control", "Absence of medical explanation"], "answer": "A", "answer_index": 0, "explanation": "Both malingering and factitious disorder involve intentional symptom production. The key distinction is motivation: malingering seeks external reward (money, avoiding work), while factitious disorder seeks the 'sick role' for psychological needs. Both have insight and voluntary control. Absence of medical explanation is common to both somatic symptom disorders.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: 35-year-old male in personal injury lawsuit (suggesting potential external incentive/secondary gain), reports severe chronic pain despite normal exams/imaging, inconsistent symptom presentation (implying intentional fabrication). Question asks for criterion distinguishing malingering from factitious disorder, where malingering involves external rewards like lawsuit compensation, versus factitious' internal psychological needs.\\nMain logical issue(s), if any: None; stem provides sufficient clues (lawsuit context, inconsistency) to discriminate A as unique best, as secondary gain is the hallmark distinguisher per DSM-5; alternatives are shared features (B, D common to both; E nonspecific; C more aligned with somatic symptom disorders).\\nMain medical accuracy issue(s), if any: None; aligns precisely with psychiatric standards—malingering defined by external incentives, factitious by assuming sick role without external gain; both intentional with insight/voluntary control.\\nMinimal fix: No fix needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: 35-year-old male in personal injury lawsuit (suggesting potential external incentive/secondary gain), reports severe chronic pain despite normal exams/imaging, inconsistent symptom presentation (implying intentional fabrication). Question asks for criterion distinguishing malingering from factitious disorder, where malingering involves external rewards like lawsuit compensation, versus factitious' internal psychological needs.\nMain logical issue(s), if any: None; stem provides sufficient clues (lawsuit context, inconsistency) to discriminate A as unique best, as secondary gain is the hallmark distinguisher per DSM-5; alternatives are shared features (B, D common to both; E nonspecific; C more aligned with somatic symptom disorders).\nMain medical accuracy issue(s), if any: None; aligns precisely with psychiatric standards—malingering defined by external incentives, factitious by assuming sick role without external gain; both intentional with insight/voluntary control.\nMinimal fix: No fix needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]